T1	AdverseReaction 54 83	Nephrogenic Systemic Fibrosis
T3	Severity 366 370	mild
T4	Severity 374 380	severe
T5	AdverseReaction 392 397	death
T6	AdverseReaction 264 290	hypersensitivity reactions
T7	AdverseReaction 296 310;337 351	cardiovascular manifestations
T8	AdverseReaction 312 323;337 351	respiratory manifestations
T9	AdverseReaction 327 351	cutaneous manifestations
T10	DrugClass 544 576	Gadolinium-based contrast agents
T12	AdverseReaction 607 636	nephrogenic systemic fibrosis
T13	AdverseReaction 638 641	NSF
T14	DrugClass 850 854	GBCA
T16	AdverseReaction 866 869	NSF
T17	AdverseReaction 1223 1226	NSF
T18	AdverseReaction 1241 1246	fatal
T23	AdverseReaction 1263 1271	fibrosis
T24	Factor 1227 1230	may
T25	AdverseReaction 2900 2912;2940 2949	Anaphylactic reactions
T26	AdverseReaction 2923 2949	hypersensitivity reactions
T27	Severity 3025 3029	mild
T28	Severity 3033 3039	severe
T29	AdverseReaction 3051 3056	death
T32	AdverseReaction 3964 3983	acute kidney injury
T33	DrugClass 4052 4057	GBCAs
T34	Factor 4362 4365	may
T35	AdverseReaction 4347 4361;4385 4395	administration irritation
T2	AdverseReaction 241 253;281 290	Anaphylactic reactions
T11	Severity 4376 4384	moderate
T19	Severity 1250 1262	debilitating
E1	AdverseReaction:T1
E3	Severity:T3
E4	Severity:T4
E5	AdverseReaction:T5
E6	AdverseReaction:T6
E7	AdverseReaction:T7 Effect:E3 Effect2:E4 Effect3:E4
E8	AdverseReaction:T8 Effect:E3
E9	AdverseReaction:T9 Effect:E3 Effect2:E4
E10	DrugClass:T10
E12	AdverseReaction:T12 Hypothetical2:E10
E13	AdverseReaction:T13 Hypothetical:E10
E14	DrugClass:T14
E16	AdverseReaction:T16 Hypothetical2:E14
E17	AdverseReaction:T17
E18	AdverseReaction:T18 Hypothetical:E24
E23	AdverseReaction:T23 Hypothetical:E24 Effect:E19
E24	Factor:T24
E25	AdverseReaction:T25 Effect:E27 Effect2:E28
E27	Severity:T27
E28	Severity:T28
E29	AdverseReaction:T29
E30	AdverseReaction:T26 Effect:E27 Effect2:E28
E33	AdverseReaction:T32 Hypothetical:E34
E34	DrugClass:T33
E35	Factor:T34
E36	AdverseReaction:T35 Hypothetical:E35 Effect:E11
E2	AdverseReaction:T2
E11	Severity:T11
E19	Severity:T19
A1	CUI E1 C3888044
A2	UMLS-Preferred-Name E1 Nephrogenic Systemic Fibrosis
A3	MEDDRA-PT E1 Nephrogenic systemic fibrosis
A4	MEDDRA-PT-ID E1 10067467
A5	CUI E5 C1306577
A6	UMLS-Preferred-Name E5 Death (finding)
A7	MEDDRA-PT E5 Death
A8	MEDDRA-PT-ID E5 10011906
A9	CUI E6 C0020517
A10	UMLS-Preferred-Name E6 Hypersensitivity
A11	MEDDRA-PT E6 Hypersensitivity
A12	MEDDRA-PT-ID E6 10020751
A13	LLT E6 Hypersensitivity reaction
A14	LLT-ID E6 10020756
A15	CUI E7 C0476270
A16	UMLS-Preferred-Name E7 Cardiovascular symptoms
A17	MEDDRA-PT E7 Cardiovascular symptom
A18	MEDDRA-PT-ID E7 10075534
A19	CUI E8 C0037090
A20	UMLS-Preferred-Name E8 Signs and Symptoms, Respiratory
A21	MEDDRA-PT E8 Respiratory symptom
A22	MEDDRA-PT-ID E8 10075535
A23	CUI E9 C0037285
A24	UMLS-Preferred-Name E9 Skin Manifestations
A25	MEDDRA-PT E9 Cutaneous symptom
A26	MEDDRA-PT-ID E9 10075531
A27	CUI E12 C3888044
A28	UMLS-Preferred-Name E12 Nephrogenic Systemic Fibrosis
A29	MEDDRA-PT E12 Nephrogenic systemic fibrosis
A30	MEDDRA-PT-ID E12 10067467
A31	CUI E13 C3888044
A32	UMLS-Preferred-Name E13 Nephrogenic Systemic Fibrosis
A33	MEDDRA-PT E13 Nephrogenic systemic fibrosis
A34	MEDDRA-PT-ID E13 10067467
A35	CUI E16 C3888044
A36	UMLS-Preferred-Name E16 Nephrogenic Systemic Fibrosis
A37	MEDDRA-PT E16 Nephrogenic systemic fibrosis
A38	MEDDRA-PT-ID E16 10067467
A39	CUI E17 C3888044
A40	UMLS-Preferred-Name E17 Nephrogenic Systemic Fibrosis
A41	MEDDRA-PT E17 Nephrogenic systemic fibrosis
A42	MEDDRA-PT-ID E17 10067467
A43	CUI E18 C1306577
A44	UMLS-Preferred-Name E18 Death (finding)
A45	MEDDRA-PT E18 Death
A46	MEDDRA-PT-ID E18 10011906
A47	CUI E23 C0016059
A48	UMLS-Preferred-Name E23 Fibrosis
A49	MEDDRA-PT E23 Fibrosis
A50	MEDDRA-PT-ID E23 10016642
A51	CUI E25 C0002792
A52	UMLS-Preferred-Name E25 anaphylaxis
A53	MEDDRA-PT E25 Anaphylactic reaction
A54	MEDDRA-PT-ID E25 10002198
A55	CUI E30 C0020517
A56	UMLS-Preferred-Name E30 Hypersensitivity
A57	MEDDRA-PT E30 Hypersensitivity
A58	MEDDRA-PT-ID E30 10020751
A59	LLT E30 Hypersensitivity reaction
A60	LLT-ID E30 10020756
A61	CUI E29 C1306577
A62	UMLS-Preferred-Name E29 Death (finding)
A63	MEDDRA-PT E29 Death
A64	MEDDRA-PT-ID E29 10011906
A65	CUI E33 C2609414
A66	UMLS-Preferred-Name E33 Acute kidney injury
A67	MEDDRA-PT E33 Acute kidney injury
A68	MEDDRA-PT-ID E33 10069339
A69	CUI E36 C3888600
A70	UMLS-Preferred-Name E36 Administration site irritation
A71	MEDDRA-PT E36 Administration site irritation
A72	MEDDRA-PT-ID E36 10075941
A73	CUI E2 C0002792
A74	UMLS-Preferred-Name E2 anaphylaxis
A75	MEDDRA-PT E2 Anaphylactic reaction
A76	MEDDRA-PT-ID E2 10002198
